TVRD — Tvardi Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $250.07m
- $212.17m
- $7.14m
- 46
- 4
- 100
- 48
Annual cashflow statement for Tvardi Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 8.41 | -88.4 | -85.5 | -119 | -70.9 |
| Depreciation | |||||
| Non-Cash Items | -6.74 | 22.8 | 19.4 | 16.8 | 27 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -7.37 | 5.26 | -12.9 | 9.36 | -17.2 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -5.49 | -60.1 | -78.7 | -92.1 | -60.9 |
| Capital Expenditures | -0.349 | -0.039 | -0.043 | -2.38 | -1.05 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -19.9 | -4.71 | 129 | 45.8 | 49.8 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -20.3 | -4.75 | 129 | 43.5 | 48.7 |
| Financing Cash Flow Items | — | — | — | 36.5 | -3.6 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 39.1 | 46.6 | 0.311 | 38.2 | -3.6 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 13.4 | -18.2 | 50.3 | -10.5 | -15.8 |